Imke Bartelink
University of California, USA
Title: Individualized treatment with an optimal risk-benefit in children using pharmacokinetic-pharmacodynamic modeling in pediatric diseases and solid tumors
Biography
Biography: Imke Bartelink
Abstract
The dose of drugs in pediatrics is routinely calculated in an empirical manner using information from adult-studies with either body surface area (BSA), bodyweight based dosing or allometric scaling, even though most developmental changes in the pharmacokinetics (PK) and pharmacodynamics (PD) are non-linear dynamic processes. The design of dosing regimens for the treatment of solid tumors in children is further complicated by the interplay between the tumor and the tumor environment. Historically, understanding such concentration-outcome relationships in children has been a challenge, due to limitations on blood volumes, invasive tumor biopsies, ethical considerations, bioanalytical sensitivity and PK modeling methodologies. However, our studies with busulfan, carboplatin and veliparib are an example that these barriers can be overcome.